A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHenan Cancer Hospital
About this trial
Given that a significant proportion of locally advanced gastric cancer patients still die from tumor recurrence after surgery, with long-term therapeutic outcomes stagnating and difficult to further improve, especially for patients with poor tumor regression grade (TRG) after surgery, this study aims to explore a new model of adjuvant therapy by conducting research on the use of Fruquintinib in combination with standard chemotherapy for postoperative treatment of HER2-negative gastric cancer patients with poor TRG, in order to bring greater survival benefits to patients.
Eligibility criteria
Qualifiers
Fully understand the study and voluntarily sign the informed consent form;
Age between 18 and 75 years;
Histologically confirmed resectable or potentially resectable locally advanced gastric/gastroesophageal junction adenocarcinoma;
Tumor Regression Grade (TRG) 2 or 3 after preoperative adjuvant therapy;
Disqualifiers
Inability to comply with the study protocol or procedures;
History of prior gastric cancer surgery;
Contraindications to surgical treatment and chemotherapy or physical condition and organ function that do not allow for major abdominal surgery;
Distant metastasis to organs other than the liver, such as lung, brain, and bone;
Trial design
Treatments tested in this trial
- Fruquintinib
Treatment groups
69 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov